Recursion Pharmaceuticals, Inc. RXRX Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s software and technology licenses, net?
- Recursion Pharmaceuticals, Inc. (RXRX) reported software and technology licenses, net of $12.25M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s software and technology licenses, net changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s software and technology licenses, net decreased by 17.1% year-over-year, from $14.78M to $12.25M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s software and technology licenses, net?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s software and technology licenses, net has grown at a 81.4% compound annual growth rate (CAGR), from $650K to $12.75M.